Lawrence Leiter, MD, FRCP(C), FACP

Lawrence Leiter, MD, FRCP(C), FACP

Head, Division of Endocrinology and Metabolism
Director, Lipid Clinic
Associate Director, Clinical Nutrition and Risk Factor Modification Centre
St. Michael’s Hospital
Professor of Medicine and Nutritional Sciences
University of Toronto
Toronto, Ontario
Canada

Related Videos

How large is the subgroup of diabetic patients who you feel are likely to appropriate candidates for PCSK9 inhibition to optimize CV risk reduction? And how does the lack of a safety signal influence your recommendations for this group? Video

How large is the subgroup of diabetic patients who you feel are likely to appropriate candidates for PCSK9 inhibition to optimize CV risk reduction? And how does the lack of a safety signal influence your recommendations for this group?

What is the rationale for a new category called “extreme risk,” introduced by AACE in which they designate a threshold LDL-C target of 55 mg/dL? Video

What is the rationale for a new category called “extreme risk,” introduced by AACE in which they designate a threshold LDL-C target of 55 mg/dL?

What is your analysis of the two major CV outcome trials and from a mortality end point perspective in what way do mortality outcome end points/results distinguish the ODYSSEY Outcomes Trial with alirocumab? Video

What is your analysis of the two major CV outcome trials and from a mortality end point perspective in what way do mortality outcome end points/results distinguish the ODYSSEY Outcomes Trial with alirocumab?

What is the profile of the diabetic patient in whom the diabetes specialist should strongly consider the LDL-C lowering and outcome-improving effects of PCSK9 inhibitors? How do we risk stratify populations for secondary prevention? Video

What is the profile of the diabetic patient in whom the diabetes specialist should strongly consider the LDL-C lowering and outcome-improving effects of PCSK9 inhibitors? How do we risk stratify populations for secondary prevention?

What is the principal take-away from the LEADER trial about the role of liraglutide in patients with T2D and CV risk factors? Video

What is the principal take-away from the LEADER trial about the role of liraglutide in patients with T2D and CV risk factors?

What is the principal take-away from the LEADER trial about the role of liraglutide in patients with T2D and CV risk factors?

What did we learn from the LEADER trial about regimen adherence with once-daily liraglutide? Video

What did we learn from the LEADER trial about regimen adherence with once-daily liraglutide?

What did we learn from the LEADER trial about regimen adherence with once-daily liraglutide?

What did we learn from the reduction in microvascular end points -- including those reflecting renal function -- reported in the LEADER trial? Video

What did we learn from the reduction in microvascular end points -- including those reflecting renal function -- reported in the LEADER trial?

What did we learn from the reduction in microvascular end points — including those reflecting renal function — reported in the LEADER trial?

What are the significant differences in time points and types of vascular benefits seen in LEADER using a GLP-1 RA vs the EMPA-REG trial which evaluated an SGLT2 inhibitor? Video

What are the significant differences in time points and types of vascular benefits seen in LEADER using a GLP-1 RA vs the EMPA-REG trial which evaluated an SGLT2 inhibitor?

What are the significant differences in time points and types of vascular benefits seen in LEADER using a GLP-1 RA vs the EMPA-REG trial which evaluated an SGLT2 inhibitor?

Given the positive results of LEADER, can you speculate on the likely mechanisms that explain the CV risk reduction that was observed? Video

Given the positive results of LEADER, can you speculate on the likely mechanisms that explain the CV risk reduction that was observed?

Given the positive results of LEADER, can you speculate on the likely mechanisms that explain the CV risk reduction that was observed?